BioVie Inc. (NASDAQ:BIVI) Short Interest Update

BioVie Inc. (NASDAQ:BIVI) was the target of a significant drop in short interest in January. As of January 31st, there was short interest totalling 1,470,000 shares, a drop of 13.5% from the January 15th total of 1,700,000 shares. Based on an average daily volume of 1,530,000 shares, the short-interest ratio is presently 1.0 days.

BioVie Stock Performance

BioVie stock traded up $0.06 during mid-day trading on Friday, reaching $1.83. The company’s stock had a trading volume of 255,845 shares, compared to its average volume of 779,341. The company has a market capitalization of $33.77 million, a price-to-earnings ratio of -0.16 and a beta of 0.47. BioVie has a 12 month low of $1.04 and a 12 month high of $33.10. The business’s 50 day simple moving average is $2.11 and its 200 day simple moving average is $2.31.

BioVie (NASDAQ:BIVI) last released its earnings results on Tuesday, February 11th. The company reported ($0.46) earnings per share for the quarter.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of BIVI. Geode Capital Management LLC grew its position in shares of BioVie by 223.3% in the 4th quarter. Geode Capital Management LLC now owns 123,408 shares of the company’s stock valued at $247,000 after acquiring an additional 85,234 shares during the period. Drive Wealth Management LLC bought a new position in shares of BioVie in the 4th quarter valued at about $120,000. Bank of Montreal Can bought a new position in shares of BioVie in the 4th quarter valued at about $100,000. Sanders Morris Harris LLC acquired a new stake in shares of BioVie during the 4th quarter worth about $85,000. Finally, Prosperity Wealth Management Inc. acquired a new stake in shares of BioVie during the 4th quarter worth about $63,000. Institutional investors own 4.59% of the company’s stock.

About BioVie

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.